Induction dose of propofol in patients using cannabis

被引:63
作者
Flisberg, P. [1 ]
Paech, M. J. [2 ]
Shah, T. [3 ]
Ledowski, T. [3 ]
Kurowski, I. [3 ]
Parsons, R.
机构
[1] Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden
[2] Univ Western Australia, Sch Med & Pharmacol, Pharmacol Unit, Perth, WA 6009, Australia
[3] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA, Australia
关键词
anaesthesia intravenous; cannabis; propofol;
D O I
10.1097/EJA.0b013e328319be59
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective An estimated 150 million people worldwide use cannabis. The effect of cannabis on anaesthetic requirements in humans does not appear to have been studied. Methods In this prospective, randomized, single-blinded study, 30 male patients using cannabis more than once per week (group Q and 30 nonusers (group NC), aged 18-50 years, were induced with propofol 1.5, 2, 2.5, 3 or 3.5 mg kg(-1). Additional doses were given when required. The primary outcome was the 50% effective dose of propofol and successful induction was determined by loss of consciousness with a bispectral index value of less than 60 and satisfactory insertion of a laryngeal mask. Propofol requirements to achieve these outcomes were recorded. Results The dose required to achieve the target bispectral index value was not significantly higher in group C, but group C required a significantly higher propofol dose to achieve laryngeal mask insertion (314.0 +/- 109.3 vs. 263.2 +/- 69.5 mg, P<0.04). The estimated effective propofol induction dose in 50-95% of patients did not significantly differ between groups. Conclusion We conclude that cannabis use increases the propofol dose required for satisfactory clinical induction when inserting a laryngeal mask. Eur J Anaesthesiol 26:192-195 (C) 2009 European Society of Anaesthesiology.
引用
收藏
页码:192 / 195
页数:4
相关论文
共 12 条
  • [1] Adverse effects of cannabis and cannabinoids
    Ashton, CH
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 1999, 83 (04) : 637 - 649
  • [2] Acute risk factors for myocardial infarction
    Culic, Viktor
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 117 (02) : 260 - 269
  • [3] Dawson DA, 2003, ALCOHOL RES HEALTH, V27, P18
  • [4] FASSOULAKI A, 1993, ANESTH ANALG, V77, P553
  • [5] Chronic ethanol consumption does not affect action of propofol on rat hippocampal acetylcholine release in vivo
    Inagawa, G
    Sato, K
    Kikuchi, T
    Nishihama, M
    Shioda, M
    Koyama, Y
    Yamada, Y
    Andoh, T
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2004, 93 (05) : 737 - 739
  • [6] Cannabis and the brain
    Iversen, L
    [J]. BRAIN, 2003, 126 : 1252 - 1270
  • [7] Pharmacological actions and therapeutic uses of cannabis and cannabinoids
    Kumar, RN
    Chambers, WA
    Pertwee, RG
    [J]. ANAESTHESIA, 2001, 56 (11) : 1059 - 1068
  • [8] Refractory delirium tremens treated with propofol: A case series
    McCowan, C
    Marik, P
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (06) : 1781 - 1784
  • [9] Cannabis abuse and anaesthesia
    Mills, PM
    Penfold, N
    [J]. ANAESTHESIA, 2003, 58 (11) : 1125 - 1125
  • [10] Pharmacokinetics of propofol administered by target-controlled infusion to alcoholic patients
    Servin, FS
    Bougeois, B
    Gomeni, R
    Mentré, F
    Farinotti, R
    Desmonts, JM
    [J]. ANESTHESIOLOGY, 2003, 99 (03) : 576 - 585